ADAKVEO® is the first and only once-monthly sickle cell disease (SCD) treatment for the prevention of VOCs1–3
ADAKVEO® 5 mg/kg is administered by intravenous (IV) infusion over 30 minutes at Weeks 0 and 2, then every 4 weeks1
ADAKVEO® provides VOC prevention with a once-monthly IV infusion1–3
Do not mix or co-administer with other drugs through the same IV line. Do not administer as IV push or bolus1
A healthcare professional should prepare the solution for infusion using aseptic techniques, using the following equation to determine the total dose and required volume of ADAKVEO® based on the patient’s body weight (kg)1
ADAKVEO® is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting suspected adverse reactions after authorisation of ADAKVEO® is important to understand the safety profile of the treatment for SCD patients.
Indication: ADAKVEO® (crizanlizumab) is indicated for the prevention of recurrent VOCs in patients with SCD who are aged 16 years and over. It can be given as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate.1
ADAKVEO® has a conditional marketing authorisation and further evidence is awaited.
Abbreviations: HC, hydroxycarbamide; HU, hydroxyurea; IV, intravenous; SCD, sickle cell disease; VOC, vaso-occlusive crisis.
- ADAKVEO® Summary of Product Characteristics.
- National Heart, Lung, and Blood Institute. SBIR Success Stories. NHLBI funding leads to promising drug candidate to prevent sickle cell pain. Available at: www.nhlbi.nih.gov/grants-and-training/fundin-opportunities-andcontacts/s... funding-leads-promisingdrug-candidate-preventsickle-cell-pain. Date accessed: March 2021.
- Ataga KI, et al. N Engl J Med. 2017;376(5):429–439.